Țară: Cipru
Limbă: greacă
Sursă: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
MELOXICAM
DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629
M01AC06
MELOXICAM
15MG
TABLETS
MELOXICAM (0071125387) 15MG
ORAL USE
Εθνική Διαδικασία
MELOXICAM
Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 10 TABS IN BLISTER(S) (210009501) 10 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 20 TABS IN BLISTER(S) (210009502) 20 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 30 TABS IN BLISTER(S) (210009503) 30 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται
COMPARATIVE TABLE ENGLISH VS GREEK PIL PACKAGE LEAFLET: INFORMATION FOR THE USER MELGESIC 7,5 MG TABLETS MELGESIC 15 MG TABLETS Meloxicam READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Melgesic is and what it is used for 2. What you need to know before you take Melgesic 3. How to take Melgesic 4. Possible side effects 5. How to store Melgesic 6. Contents of the pack and other information 1. WHAT MELGESIC IS AND WHAT IT IS USED FOR Melgesic contains the active substance meloxicam. Meloxicam belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) which are used to reduce inflammation and pain in joints and muscles. Melgesic tablets are indicated in adults and children aged 16 years and ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ: ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΤΟV ΧΡΉΣΤΗ MELGESIC 7,5 MG ΔΙΣΚΊΑ MELGESIC 15 MG ΔΙΣΚΊΑ Μελοξικάμη ΔΙΑΒΆΣΤΕ ΠΡΟΣΕΚΤΙΚΆ ΟΛΌΚΛΗΡΟ ΤΟ ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ ΠΡΙΝ ΑΡΧΊΣΕΤΕ ΝΑ ΠΑΊΡΝΕΤΕ ΑΥΤΌ ΤΟ ΦΆΡΜΑΚΟ, ΔΙΌΤΙ ΠΕΡΙΈΧΕΙ ΣΗΜΑΝΤΙΚΈΣ ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΣΑΣ. Φυλάξτε αυτό το φύλλο οδηγιών χρήσης. Ίσως χρειαστεί να το διαβάσετε ξανά. Εάν έχετε περαιτέρω απορίες, ρωτήστε το γιατρό ή το φαρμακοποιό σας. Η συνταγή για αυτό το φάρμακο χορηγήθηκε αποκλειστικ Citiți documentul complet
1. NAME OF THE MEDICINAL PRODUCT Melgesic 7.5 mg Tablets Melgesic 15 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 7.5 mg meloxicam. Excipient(s) with known effect: each tablet contains 71.30 mg of lactose Each tablet contains 15 mg meloxicam. Excipient(s) with known effect: each tablet contains 142.60 mg of lactose For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets For 7.5mg strength: Light yellow, round, flat tablet, 8mm diameter, cross-scored on one side. For 15mg strength: Light yellow, round, concave tablet, 10mm diameter, scored on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Short-term symptomatic treatment of exacerbations of osteoarthrosis. - Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use The total daily amount should be taken as a single dose, with water or another liquid, during a meal. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis. 1 SUMMARY OF PRODUCT CHARACTERISTICS - Exacerbations of osteoarthrosis: 7.5 mg/day. If necessary, in the absence of improvement, the dose may be increased to 15 mg/day. - Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day. (see also section 'Special populations' below) According to the therapeutic response, the dose may be reduced to 7.5 mg/day. DO NOT EXCEED THE DOSE OF 15 MG/DAY. Special populations _Elderly patients and patients with increased risks for adverse reaction (see section 5.2):_ The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day (see section 4.4). _Renal impairment (see sectio Citiți documentul complet